Table 1.
Characteristics of the study population.
| All Patients (n = 62) |
Intervention Group (n = 42) |
Control Group (n = 20) |
p-Value * | |
|---|---|---|---|---|
| Gender (m/f) | 40/22 | 25/17 | 15/5 | 0.234 |
| Age at time of diagnosis 1 | 59 ± 13 | 61 ± 11 | 54 ± 17 | 0.219 |
| Diagnosis, n (%) 2 | 0.001 | |||
| Esophageal cancer | 13 (21.0) | 11 (26.2) | 2 (10,0) | |
| Cancer of the | 16 (25.8) | 15 (35.7) | 1 (5.0) | |
| gastroesophageal junction | ||||
| Gastric cancer | 25 (40.3 | 14 (33.3) | 11 (55.0) | |
| CDH1 gene mutation | 8 (12.9) | 2 (4.8) | 6 (30.0) | |
| UICC stage of disease, n (%) 2 | ||||
| 0 | 3 (5.0) | 3 (7.3) | 0 (0.0) | |
| I | 25 (41.7) | 13 (31.7) | 12 (63.2) | |
| II | 16 (26.7) | 14 (34.1) | 2 (10.5) | 0.114 |
| III | 11 (18.3) | 8 (19.5) | 3 (15.8) | |
| IV | 5 (8.3) | 2 (10.5) | 2 (10.5) | |
| Time between diagnosis and surgery (days)1 | 80 ± 49 | 93 ± 40 | 52 ± 54 | 0.009 |
| Treatment before surgery, n (%) 2 | 0.036 | |||
| No treatment | 23 (37.1) | 11 (26.2) | 12 (60.0) | |
| Chemotherapy | 30 (48.4) | 24 (57.1) | 6 (30.0) | |
| Radiochemotherapy | 9 (14.5) | 7 (16.7) | 2 (10.0) | |
| Treatment after surgery, n (%) 2 | ||||
| Chemotherapy | 19 (30.6) | 15 (35.7) | 4 (20.0) | 0.210 |
1 Data presented as mean ± standard deviation (SD), 2 data presented as absolute frequency (relative frequency in %) * Significance level p ≤ 0.05.